Brazer Noah, Morris Mary Kate, Servellita Venice, Oseguera Miriam, Sumimoto Nanami, Saldhi Prachi, Foresythe Abiodun, Nguyen Jenny, Wadford Debra A, Hanson Carl, Chiu Charles Y
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.
Sci Rep. 2025 Jul 3;15(1):23718. doi: 10.1038/s41598-025-07702-2.
The emergence of the Omicron variant in late 2021 gave rise to multiple descendent lineages, or sublineages, with progressively increased capacity for antibody evasion. Here we used live virus neutralization assays to quantify and compare homologous ("self") and cross-neutralizing antibody titers in 170 COVID-19 patients infected with either the Delta variant or an Omicron sublineage (BA.1, BA.2, BA.4/BA.5, BQ.1.1, and XBB.1.5) and 25 uninfected controls who had received the BA.5 bivalent booster vaccine. In control subjects, neutralizing antibody titers against BA.5 and earlier sublineages were significantly higher than against the later BQ.1.1 or XBB.1.5 sublineages, and differences in antibody titers between immunocompetent and immunocompromised individuals were not significant. In patients infected with an Omicron sublineage, induced cross-neutralizing antibody responses were weaker and less durable against later compared to earlier sublineages. Self-neutralizing antibody titers against BQ.1.1 or XBB.1.5 in patients infected with these sublineages were also lower than cross-neutralizing titers against earlier sublineages. Our results suggest that immunological imprinting resulting from prior exposure to SARS-CoV-2 ("original antigenic sin"), whether via natural infection or vaccination, may have impaired neutralizing antibody responses to the later Omicron sublineages. The poorer elicited immunogenicity and increased capacity for antibody evasion of these sublineages explain in part their persistence and ongoing global circulation.
2021年末出现的奥密克戎变种产生了多个衍生谱系或亚谱系,其抗体逃逸能力逐渐增强。在此,我们使用活病毒中和试验,对170名感染了德尔塔变种或奥密克戎亚谱系(BA.1、BA.2、BA.4/BA.5、BQ.1.1和XBB.1.5)的新冠肺炎患者以及25名接种了BA.5二价加强疫苗的未感染对照者的同源(“自身”)中和抗体滴度和交叉中和抗体滴度进行了量化和比较。在对照受试者中,针对BA.5及更早亚谱系的中和抗体滴度显著高于针对更晚的BQ.1.1或XBB.1.5亚谱系的滴度,免疫功能正常和免疫功能低下个体之间的抗体滴度差异不显著。在感染奥密克戎亚谱系的患者中,诱导产生的交叉中和抗体反应相较于更早的亚谱系,对更晚出现的亚谱系反应更弱且持续时间更短。感染这些亚谱系的患者针对BQ.1.1或XBB.1.5的自身中和抗体滴度也低于针对更早亚谱系的交叉中和滴度。我们的结果表明,先前接触过严重急性呼吸综合征冠状病毒2(SARS-CoV-2)(“原始抗原原罪”)所导致的免疫印记,无论是通过自然感染还是疫苗接种,可能损害了对更晚出现的奥密克戎亚谱系的中和抗体反应。这些亚谱系引发的免疫原性较差以及抗体逃逸能力增强,部分解释了它们的持续存在和在全球范围内的持续传播。